451 related articles for article (PubMed ID: 27476094)
21. Immediate and 1-year follow-up with the novel nanosurface modified COBRA PzF stent.
Maillard L; Tavildari A; Barra N; Billé J; Joly P; Peycher P; Silvestri M; Vochelet F
Arch Cardiovasc Dis; 2017 Dec; 110(12):682-688. PubMed ID: 29102364
[TBL] [Abstract][Full Text] [Related]
22. Everolimus- Versus Novolimus-Eluting Bioresorbable Scaffolds for the Treatment of Coronary Artery Disease: A Matched Comparison.
Wiebe J; Dörr O; Ilstad H; Husser O; Liebetrau C; Boeder N; Bauer T; Möllmann H; Kastrati A; Hamm CW; Nef HM
JACC Cardiovasc Interv; 2017 Mar; 10(5):477-485. PubMed ID: 28216214
[TBL] [Abstract][Full Text] [Related]
23. Clinical results of single and multiple bioresorbable drug-eluting scaffolds for treatment of de-novo coronary artery disease.
Markovic S; Dragomir S; Walcher D; Bernhardt P; Imhof A; Rottbauer W; Wöhrle J
Coron Artery Dis; 2016 Nov; 27(7):561-5. PubMed ID: 27244371
[TBL] [Abstract][Full Text] [Related]
24. Everolimus-eluting bioresorbable scaffolds for treatment of coronary artery disease in patients with diabetes mellitus: the midterm follow-up of the prospective ABSORB DM Benelux study.
Hommels TM; Hermanides RS; Rasoul S; Berta B; IJsselmuiden AJJ; Jessurun GAJ; Benit E; Pereira B; De Luca G; Kedhi E
Cardiovasc Diabetol; 2019 Mar; 18(1):25. PubMed ID: 30851731
[TBL] [Abstract][Full Text] [Related]
25. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y
Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593
[TBL] [Abstract][Full Text] [Related]
26. The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial.
Suwannasom P; Sotomi Y; Ishibashi Y; Cavalcante R; Albuquerque FN; Macaya C; Ormiston JA; Hill J; Lang IM; Egred M; Fajadet J; Lesiak M; Tijssen JG; Wykrzykowska JJ; de Winter RJ; Chevalier B; Serruys PW; Onuma Y
JACC Cardiovasc Interv; 2016 Jun; 9(12):1231-1242. PubMed ID: 27262861
[TBL] [Abstract][Full Text] [Related]
27. Clinical outcomes of patients with diabetes mellitus treated with Absorb bioresorbable vascular scaffolds: a subanalysis of the European Multicentre GHOST-EU Registry.
Capranzano P; Capodanno D; Brugaletta S; Latib A; Mehilli J; Nef H; Gori T; Lesiak M; Geraci S; Pyxaras S; Mattesini A; Münzel T; Araszkiewicz A; Caramanno G; Naber C; Di Mario C; Sabatè M; Colombo A; Wiebe J; Tamburino C
Catheter Cardiovasc Interv; 2018 Feb; 91(3):444-453. PubMed ID: 29068130
[TBL] [Abstract][Full Text] [Related]
28. 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: a pooled analysis of the ABSORB and the SPIRIT trials.
Muramatsu T; Onuma Y; van Geuns RJ; Chevalier B; Patel TM; Seth A; Diletti R; García-García HM; Dorange CC; Veldhof S; Cheong WF; Ozaki Y; Whitbourn R; Bartorelli A; Stone GW; Abizaid A; Serruys PW; ; ; ; ; ;
JACC Cardiovasc Interv; 2014 May; 7(5):482-93. PubMed ID: 24746650
[TBL] [Abstract][Full Text] [Related]
29. Incidence and short-term clinical outcomes of small side branch occlusion after implantation of an everolimus-eluting bioresorbable vascular scaffold: an interim report of 435 patients in the ABSORB-EXTEND single-arm trial in comparison with an everolimus-eluting metallic stent in the SPIRIT first and II trials.
Muramatsu T; Onuma Y; García-García HM; Farooq V; Bourantas CV; Morel MA; Li X; Veldhof S; Bartorelli A; Whitbourn R; Abizaid A; Serruys PW;
JACC Cardiovasc Interv; 2013 Mar; 6(3):247-57. PubMed ID: 23517836
[TBL] [Abstract][Full Text] [Related]
30. Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy.
Yamaji K; Brugaletta S; Sabaté M; Iñiguez A; Jensen LO; Cequier A; Hofma SH; Christiansen EH; Suttorp M; van Es GA; Sotomi Y; Onuma Y; Serruys PW; Windecker S; Räber L
JACC Cardiovasc Interv; 2017 Sep; 10(18):1867-1877. PubMed ID: 28935079
[TBL] [Abstract][Full Text] [Related]
31. Clinical, Angiographic, Functional, and Imaging Outcomes 12 Months After Implantation of Drug-Eluting Bioresorbable Vascular Scaffolds in Acute Coronary Syndromes.
Gori T; Schulz E; Hink U; Kress M; Weiers N; Weissner M; Jabs A; Wenzel P; Capodanno D; Münzel T
JACC Cardiovasc Interv; 2015 May; 8(6):770-777. PubMed ID: 25999097
[TBL] [Abstract][Full Text] [Related]
32. Economic Outcomes of Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Stents in Patients Undergoing Percutaneous Coronary Intervention: 1-Year Results From the ABSORB III Trial.
Baron SJ; Lei Y; Chinnakondepalli K; Vilain K; Magnuson EA; Kereiakes DJ; Ellis SG; Stone GW; Cohen DJ;
JACC Cardiovasc Interv; 2017 Apr; 10(8):774-782. PubMed ID: 28427593
[TBL] [Abstract][Full Text] [Related]
33. Clinical results of bioresorbable drug-eluting scaffolds in short and long coronary artery lesions using the PSP technique.
Reichart C; Wöhrle J; Markovic S; Rottbauer W; Seeger J
BMC Cardiovasc Disord; 2019 Jan; 19(1):22. PubMed ID: 30658574
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the Safety of Everolimus-Eluting Bioresorbable Vascular Scaffold (BVS) Implantation in Patients With Chronic Total Coronary Occlusions: Acute Procedural and Short-Term Clinical Results.
Goktekin O; Yamac AH; Latib A; Tastan A; Panoulas VF; Sato K; Erdogan E; Uyarel H; Shah I; Colombo A
J Invasive Cardiol; 2015 Oct; 27(10):461-6. PubMed ID: 26429848
[TBL] [Abstract][Full Text] [Related]
35. The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial.
Tijssen RYG; Kerkmeijer LSM; Katagiri Y; Kraak RP; Takahashi K; Kogame N; Chichareon P; Modolo R; Asano T; Nassif M; Kalkman DN; Sotomi Y; Collet C; Hofma SH; van der Schaaf RJ; Arkenbout EK; Weevers APJD; Beijk MAM; Piek JJ; Tijssen JGP; Henriques JP; de Winter RJ; Onuma Y; Serruys PW; Wykrzykowska JJ
Int J Cardiovasc Imaging; 2019 Jul; 35(7):1189-1198. PubMed ID: 30911857
[TBL] [Abstract][Full Text] [Related]
36. Overview of the 2016 U.S. Food and Drug Administration Circulatory System Devices Advisory Panel Meeting on the Absorb Bioresorbable Vascular Scaffold System.
Steinvil A; Rogers T; Torguson R; Waksman R
JACC Cardiovasc Interv; 2016 Sep; 9(17):1757-64. PubMed ID: 27609249
[TBL] [Abstract][Full Text] [Related]
37. One-year clinical performance of ABSORB bioresorbable vascular scaffold in patients presenting with acute coronary syndromes: Results from the RAI registry.
Moscarella E; Ielasi A; Varricchio A; Cortese B; Loi B; Tarantini G; Pisano F; Durante A; Pasquetto G; Colombo A; Tumminello G; Moretti L; Calabrò P; Mazzarotto P; Tespili M; Silva Orrego P; Corrado D; Steffenino G;
Catheter Cardiovasc Interv; 2019 Feb; 93(3):404-410. PubMed ID: 30346080
[TBL] [Abstract][Full Text] [Related]
38. Percutaneous coronary interventions with the Absorb Bioresorbable vascular scaffold in real life: 1-year results from the FRANCE ABSORB registry.
Cayla G; Koning R; Fajadet J; Sainsous J; Carrié D; Elhadad S; Tarragano F; Lefévre T; Ranc S; Ghostine S; Garot P; Marco F; Maillard L; Motreff P; Le Breton H;
Arch Cardiovasc Dis; 2019 Feb; 112(2):113-123. PubMed ID: 30630761
[TBL] [Abstract][Full Text] [Related]
39. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: Results of the ISAR-ABSORB registry.
Hoppmann P; Kufner S; Cassese S; Wiebe J; Schneider S; Pinieck S; Scheler L; Bernlochner I; Joner M; Schunkert H; Laugwitz KL; Kastrati A; Byrne RA
Catheter Cardiovasc Interv; 2016 Apr; 87(5):822-9. PubMed ID: 26708019
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and Safety of the Absorb Bioresorbable Vascular Scaffold in Females and Males: Results of an Individual Patient-Level Pooled Meta-Analysis of Randomized Controlled Trials.
Shreenivas S; Kereiakes DJ; Ellis SG; Gao R; Kimura T; Onuma Y; Piard-Ruster K; Zhang Y; Koo K; Vu MT; Serruys PW; Stone GW
JACC Cardiovasc Interv; 2017 Sep; 10(18):1881-1890. PubMed ID: 28935081
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
